MarketCapExport financials
PTC Therapeutics (PTCT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
PTC Therapeutics Cash Flow 2025-2010 | PTCT
Brief overview of PTC Therapeutics's cash flow quality
This overview follows the five latest available annual observations in the 2021–2025 interval.
Operating cash flow recovered from negative territory and reached $711.2 million. Core operations returned to generating cash.
Positive operating cash flow appeared only 1 times out of five; a stable cash profile has not formed.
Operating cash margin reached 41.1% versus -46.7% initially. Revenue converted into cash more effectively.
Working capital grew $112.5 million, or 6.5% of sales. Part of cash generation funded day-to-day operations.
Conclusion
PTC Therapeutics's profile is moderate, with strengths in cash generation offset by factors that constrain free cash.
Annual Cash Flow PTC Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
711 M | -108 M | -158 M | -357 M | -251 M | -194 M | -98.6 M | -27.6 M | -10.1 M | -104 M | -124 M | -57.3 M | - | - | - | - |
Depreciation & Amortization |
38.8 M | 75.7 M | 237 M | 129 M | 64.1 M | 43.5 M | 32.2 M | 26.1 M | 17.7 M | 3.29 M | 2.88 M | 2.24 M | 2.4 M | 2.7 M | 2.87 M | - |
Accounts Payables |
45.5 M | 17.3 M | 6.04 M | 27.3 M | 23 M | 18.7 M | 10.3 M | 6 M | 15.3 M | 6.3 M | 11.9 M | 4.13 M | 1.12 M | - | - | - |
Accounts Receivables |
182 M | 159 M | 161 M | 156 M | 110 M | 69.9 M | 55.5 M | 67.9 M | 40.4 M | 24.9 M | 11.1 M | 4.44 M | - | - | - | - |
Total Inventories |
79.6 M | 23.2 M | 30.6 M | 21.8 M | 15.9 M | 18.7 M | 19.3 M | 16.1 M | 10.8 M | 1.7 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow PTC Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
70.1 M | -59 M | - | - | 870 M | - | - | - | 70.8 M | - | - | - | -29.5 M | - | -191 M | - | -97.4 M | - | -182 M | - | -100 M | - | -130 M | -156 M | -81.6 M | - | -88.4 M | -72.9 M | -42.4 M | - | -12.5 M | -15.9 M | -15.9 M | - | -31.4 M | -15.6 M | -28.9 M | - | -90.2 M | -66.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
31.3 M | 15.4 M | 7.53 M | 4.06 M | 7.22 M | - | 3.04 M | 2.86 M | 55.4 M | - | 58.6 M | 47.4 M | 42.8 M | - | 31 M | 26.3 M | 26.3 M | - | 45.3 M | 12.8 M | 13.6 M | - | 31.1 M | 19.4 M | 9.24 M | - | 22.9 M | 14.8 M | 7.06 M | - | 19.3 M | 12.2 M | 6.02 M | - | 11.7 M | 1.45 M | 612 K | - | 2.48 M | 1.66 M | 849 K | - | 2.08 M | 1.32 M | 634 K | - | 1.69 M | 1.15 M | 588 K | - | 1.81 M | 1.22 M | 625 K | - | 2.05 M | 1.38 M | - | - | - | - | - |
Accounts Payables |
40.4 M | 25.5 M | 36.6 M | 26.5 M | 15.2 M | 17.3 M | 13.3 M | 24.3 M | 27.5 M | 6.04 M | 19.2 M | 25.7 M | 26.3 M | 27.3 M | 20.9 M | - | 18.4 M | 23 M | 21.5 M | 20.8 M | 19.1 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 6 M | 6 M | 6 M | 6 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 5.78 M | 11.9 M | 11.9 M | 11.9 M | 4.13 M | 4.13 M | 4.13 M | 4.13 M | 1.12 M | 1.12 M | 1.12 M | 1.12 M | 622 K | 622 K | 622 K | - | - | - | - | - |
Accounts Receivables |
239 M | 220 M | 203 M | 196 M | 210 M | 159 M | 200 M | 187 M | 198 M | 161 M | 166 M | 178 M | 202 M | 156 M | 124 M | - | 141 M | 110 M | 96.6 M | 78.8 M | 94.1 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 67.9 M | 67.9 M | 67.9 M | 67.9 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 4.44 M | 4.44 M | 4.44 M | 4.44 M | 958 K | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
91.4 M | 75.6 M | 52.7 M | 34.1 M | 21.7 M | 23.2 M | 35.7 M | 31.8 M | 30.1 M | 30.6 M | 35.8 M | 32 M | 26.6 M | 21.8 M | 14.8 M | - | 15.3 M | 15.9 M | 15.6 M | 16.4 M | 16.2 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company PTC Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Revolution Medicines
RVMD
|
$ 194.28 | -1.15 % | $ 36.9 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 88.62 | -1.75 % | $ 5.76 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.65 | 3.4 % | $ 281 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.35 | -0.42 % | $ 595 M | USA |
 |
Zai Lab Limited
ZLAB
|
$ 24.2 | -3.51 % | $ 26.5 B |  China |
 |
Pulmatrix
PULM
|
$ 1.57 | 9.79 % | $ 5.73 B | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.36 | -1.26 % | $ 170 M | USA |
 |
Zoetis
ZTS
|
$ 79.62 | -0.52 % | $ 35.3 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.92 | -0.62 % | $ 1.57 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.87 | -3.61 % | $ 1.26 B |  Israel |
 |
AC Immune SA
ACIU
|
$ 2.47 | -0.8 % | $ 249 M |  Schweiz |
 |
Adagene
ADAG
|
$ 2.41 | -3.6 % | $ 142 M | China |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.11 | 7.59 % | $ 2.75 M | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.5 | -1.32 % | $ 191 M | Schweiz |
 |
ADMA Biologics
ADMA
|
$ 11.01 | -1.96 % | $ 2.62 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 20.46 | -3.45 % | $ 229 M | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.33 | -0.38 % | $ 293 M | USA |
 |
Amgen
AMGN
|
$ 438.34 | -0.14 % | $ 236 B | USA |
 |
Ardelyx
ARDX
|
$ 3.13 | -2.49 % | $ 754 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.06 | -4.38 % | $ 111 M | USA |
 |
Artelo Biosciences
ARTL
|
$ 2.56 | -2.29 % | $ 484 K | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.57 | -0.83 % | $ 247 M |  Britain |
 |
Beam Therapeutics
BEAM
|
$ 24.84 | -0.36 % | $ 2.46 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 8.5 | -5.97 % | $ 396 M | USA |
 |
BioNTech SE
BNTX
|
$ 91.29 | 0.13 % | $ 22.1 B |  Germany |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.24 | -0.59 % | $ 1.45 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.17 | 0.32 % | $ 263 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.39 | 3.46 % | $ 456 M | USA |
 |
Certara
CERT
|
$ 10.18 | 4.04 % | $ 1.63 B | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.02 | 2.0 % | $ 119 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 116.28 | -0.15 % | $ 12.1 B | USA |
 |
CorMedix
CRMD
|
$ 7.79 | 2.91 % | $ 561 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.5 | 1.24 % | $ 4.54 B | Schweiz |
 |
Greenwich LifeSciences
GLSI
|
$ 16.57 | 2.03 % | $ 224 M | USA |
 |
Champions Oncology
CSBR
|
$ 4.85 | 0.83 % | $ 67.1 M | USA |
 |
Cue Biopharma
CUE
|
$ 18.95 | 11.21 % | $ 1.8 B | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 9.62 | 1.48 % | $ 1.34 B |  France |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.39 | 0.84 % | $ 15.3 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.38 | -1.43 % | $ 43.1 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 8.69 | 0.23 % | $ 408 M | USA |